Cognitive-enhancing effects of aripiprazole: A case report

Clinical Practice and Epidemiology in Mental Health

Volumn 4, Issue , 2008, Pages

  Mucci, Armida ^a   Piegari, Giuseppe ^a   Galderisi, Silvana ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COGNITION; COGNITIVE THERAPY; DOPAMINE RELEASE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HUMAN; MALE; ONSET AGE; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; PSYCHOTHERAPY; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL STATUS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 56649122129     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-4-24     Document Type: Article

References (11)

1. Heinrichs RW Zakzanis KK Neurocognitive deficit in schizophrenia: A quantitative review of the evidence Neuropsychology 1998, 12:426-45. 10.1037/0894-4105.12.3.426 9673998
2. Green MF Kern RS Braff DL Mintz J Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 2000, 26:119-36. 10755673
3. Bilder RM Goldman RS Volavka J Czobor P Hoptman M Sheitman B Lindenmayer JP Citrome L McEvoy J Kunz M Chakos M Cooper TB Horowitz TL Lieberman JA Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder Am J Psychiatry 2002, 159:1018-28. 10.1176/appi.ajp.159.6.1018 12042192
4. Keefe RS Silva SG Perkins DO Lieberman JA The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophr Bull 1999, 25:201-22. 10416727
5. Woodward ND Purdon SE Meltzer HY Zald DH A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia Int J Neuropsychopharmacol 2005, 8:457-72. 10.1017/S146114570500516X 15784157
6. Li Z Ichikawa J Dai J Meltzer HY Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur J Pharmacol 2004, 493:75-83. 10.1016/ j.ejphar.2004.04.028 15189766
7. Kern RS Green MF Cornblatt BA Owen JR McQuade RD Carson WH Ali M Marcus R The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine Psychopharmacology 2006, 187:312-20. 10.1007/ s00213-006-0428-x 16810506
8. Voruganti LP Awad AG Parker G Forrest C Usmani Y Fernando ML Senthilal S Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine Schizophr Res 2007, 96:146-55. 10.1016/j.schres.2007.08.002 17728106
9. Keefe RS Sweeney JA Gu H Hamer RM Perkins DO McEvoy JP Lieberman JA Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison Am J Psychiatry 2007, 164(7):1061-71. 10.1176/ appi.ajp.164.7.1061 17606658
10. Meltzer HY Sumiyoshi T Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 2008;18707769.
11. Yulug B Yildiz A Hüdaoglu O Kilic E Cam E Schäbitz WR Olanzapine attenuates brain damage after focal cerebral ischemia in vivo Brain Res Bull 2006, 71:296-300. 10.1016/j.brainresbull.2006.09.018 17113959